Sign in
BCTX Stock Price, Chart, Stats & News
BriaCell Therapeutics Corp.
Save
BriaCell Therapeutics Corp. (BCTX) does not currently pay a dividend.
35.50M
Market cap
–
Current P/E
–
Forward P/E
BCTX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -114.22% |
ROE | -187.33% |
D/E | – |
Interest coverage ratio | -756.02x |
BCTX valuation
P/E | – |
P/S | – |
P/B | 0.35x |
P/CF | -0.28x |
P/FCF | -0.19x |
P/OCF | -0.28x |
PEG | -0.01x |
EV multiple | -0.89x |
About
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer.
Similar securities
Based on sector and market capitalization
Report issue